Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Prelude Therapeutics IncPRLD · Entity 5561 | Director · CEO | February 04, 2026 | February 05, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Prelude Therapeutics Inc
Report date February 04, 2026 · Filed February 05, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.30 · Expires 2036-02-03 | Direct | 837,000 |
Reported balance
After 2026-02-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-04 · Grant · Acquired 837,000 · Balance 837,000 F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 04, 2026 Filed Feb 5, 2026 21:10 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 837,000 | $0.00 Strike: $2.30 | $0.00 |
DisclosureSEC source: 0001824633-26-000002 · primarydocument.xml · derivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 837,000 Underlying: Common Stock · 837,000 shares Expires 2036-02-03 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2027, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| March 25, 2025 Filed Mar 27, 2025 20:37 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 675,000 | $0.69 | $467,437.50 |
DisclosureSEC source: 0001562180-25-002778 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,999,296 Read SEC document |
| March 21, 2025 Filed Mar 24, 2025 21:03 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 15,000 | $0.73 | $10,959.00 |
DisclosureSEC source: 0001562180-25-002697 · primarydocument.xml · nonDerivative · entry 2 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,324,296 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.73 to $0.731, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 20, 2025 Filed Mar 24, 2025 21:03 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 5,416 | $0.73 | $3,950.43 |
DisclosureSEC source: 0001562180-25-002697 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,309,296 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7294 to $0.73, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 20:27 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 9,106 | $0.75 | $6,828.59 |
DisclosureSEC source: 0001562180-25-002541 · primarydocument.xml · nonDerivative · entry 2 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,303,880 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7496 to $0.75, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 14, 2025 Filed Mar 18, 2025 20:27 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 29,999 | $0.75 | $22,631.25 |
DisclosureSEC source: 0001562180-25-002541 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,294,774 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.7746 to $0.7782, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 13, 2025 Filed Mar 14, 2025 12:02 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 50,000 | $0.72 | $35,820.00 |
DisclosureSEC source: 0001562180-25-002392 · primarydocument.xml · nonDerivative · entry 2 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,264,775 F2 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.6993 to $0.7999, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 12, 2025 Filed Mar 14, 2025 12:02 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 47,500 | $0.71 | $33,744.00 |
DisclosureSEC source: 0001562180-25-002392 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,214,775 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.693 to $0.7512, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| February 04, 2025 Filed Feb 5, 2025 21:30 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 496,000 | $0.00 Strike: $1.11 | $0.00 |
DisclosureSEC source: 0001562180-25-000955 · primarydocument.xml · derivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 496,000 Underlying: Common Stock · 496,000 shares Expires 2035-02-04 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on Feb 4, 2026, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 31, 2024 Filed Jan 3, 2025 12:41 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 5,000 | $1.21 | $6,043.50 |
DisclosureSEC source: 0001562180-25-000031 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 142,553 F1 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 30, 2024 Filed Jan 2, 2025 21:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 10,000 | $1.20 | $12,000.00 |
DisclosureSEC source: 0001562180-25-000008 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 137,553 F1 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 19, 2024 Filed Dec 20, 2024 12:33 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 6,888 | $0.89 | $6,115.86 |
DisclosureSEC source: 0001562180-24-008531 · primarydocument.xml · nonDerivative · entry 2 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Indirect · See footnote Disclosed balance after: 127,553 F2 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| December 18, 2024 Filed Dec 20, 2024 12:33 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 100,000 | $0.93 | $93,210.00 |
DisclosureSEC source: 0001562180-24-008531 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,167,275 F1 · price: 1. The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $0.89 to $1.00, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. Read SEC document |
| March 01, 2024 Filed Mar 4, 2024 22:59 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 425,000 | $0.00 Strike: $4.59 | $0.00 |
DisclosureSEC source: 0001562180-24-002127 · primarydocument.xml · derivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 425,000 Underlying: Common Stock · 425,000 shares Expires 2034-02-28 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on March 1, 2025, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| May 25, 2023 Filed May 26, 2023 20:20 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 900 | $5.31 | $4,779.00 |
DisclosureSEC source: 0001562180-23-004517 · primarydocument.xml · nonDerivative · entry 2 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,067,275 F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| May 24, 2023 Filed May 26, 2023 20:20 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 1,000 | $5.01 | $5,011.40 |
DisclosureSEC source: 0001562180-23-004517 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,066,375 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.99 to $5.02, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| May 23, 2023 Filed May 25, 2023 20:03 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 11,856 | $5.63 | $66,749.28 |
DisclosureSEC source: 0001562180-23-004474 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,065,375 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.45 to $5.80, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| February 07, 2023 Filed Feb 9, 2023 21:07 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 330,000 | $0.00 Strike: $7.20 | $0.00 |
DisclosureSEC source: 0001562180-23-001166 · primarydocument.xml · derivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 330,000 Underlying: Common Stock · 330,000 shares Expires 2033-02-06 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 7, 2024, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 20, 2022 Filed Dec 21, 2022 21:08 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | PurchaseCommon Stock | 19,188 | $5.13 | $98,445.95 |
DisclosureSEC source: 0001562180-22-008404 · primarydocument.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 120,665 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $5.03 to $5.18, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| February 15, 2022 Filed Feb 18, 2022 00:09 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (right to buy) · Derivative | 327,900 | $0.00 Strike: $10.58 | $0.00 |
DisclosureSEC source: 0001209191-22-011035 · doc4.xml · derivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 327,900 Underlying: Common Stock · 327,900 shares Expires 2032-02-14 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on February 15, 2023, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| December 13, 2021 Filed Dec 14, 2021 22:36 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantCommon Stock | 8,000 | $12.13 | $97,035.20 |
DisclosureSEC source: 0001209191-21-069547 · doc4.xml · nonDerivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,053,519 F1 · price: The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $12.01 to $12.20, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the ranges set forth herein. F2 · balance_after: Certain of the shares are subject to forfeiture to the Issuer if underlying vesting conditions are not met. Read SEC document |
| July 20, 2021 Filed Jul 22, 2021 22:16 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | GrantEmployee Stock Option (Right to Buy) · Derivative | 285,800 | $0.00 Strike: $31.23 | $0.00 |
DisclosureSEC source: 0001209191-21-047845 · doc4.xml · derivative · entry 1 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 285,800 Underlying: Common Stock · 285,800 shares Expires 2031-07-19 F1 · derivative.exercise_date: The stock option vests as to 25% of the total shares on July 20, 2022, and thereafter vests as to 1/48 of the total shares monthly until fully vested, subject to the Reporting Person's provision of service to the Issuer on each vesting date. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionSeries A Preferred Stock · Derivative | 32,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052399 · doc4.xml · derivative · entry 8 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 32,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F5 · ownership.nature: The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionSeries A Preferred Stock · Derivative | 32,876 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052399 · doc4.xml · derivative · entry 7 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 0 Underlying: Common Stock · 32,876 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F4 · ownership.nature: The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionSeries A Preferred Stock · Derivative | 101,477 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-052399 · doc4.xml · derivative · entry 6 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 0 Underlying: Common Stock · 101,477 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F2 · derivative.exercise_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F2 · derivative.expiration_date: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F3 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionCommon Stock | 32,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052399 · doc4.xml · nonDerivative · entry 4 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 551,774 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F5 · ownership.nature: The Reporting Person is the investment advisor of the Brocade Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionCommon Stock | 32,876 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052399 · doc4.xml · nonDerivative · entry 3 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 551,776 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F4 · ownership.nature: The Reporting Person is the investment advisor of the Blue Sky Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
| September 29, 2020 Filed Sep 30, 2020 00:06 UTC | Prelude Therapeutics Inc PRLD · Entity 5561 | ConversionCommon Stock | 101,477 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-20-052399 · doc4.xml · nonDerivative · entry 2 Vaddi Krishna · CIK 0001824633 · Director · President, CEO 10b5-1 filing: Not disclosed Ownership: Indirect · See Footnote Disclosed balance after: 101,477 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series A Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering on September 29, 2020 and had no expiration date. F3 · ownership.nature: The Reporting Person is the manager of Sidus Ventures LLC. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.